Portal de Periódicos da CAPES

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization

2019; Springer Science+Business Media; Volume: 27; Issue: 2 Linguagem: Inglês

10.1007/s12350-019-01761-5

1532-6551

Sharmila Dorbala, Yukio Ando, Sabahat Bokhari, Angela Dispenzieri, Rodney H. Falk, Victor A. Ferrari, Marianna Fontana, Olivier Gheysens, Julian D. Gillmore, Andor W. J. M. Glaudemans, Mazen Hanna, Bouke P. C. Hazenberg, Arnt V. Kristen, Raymond Y. Kwong, Matthew J. Maurer, Giampaolo Merlini, Edward J. Miller, James Moon, Venkatesh L. Murthy, Cristina Quarta, Claudio Rapezzi, Frederick L. Ruberg, Sanjiv J. Shah, Riemer H. J. A. Slart, Hein J. Verberne, Jamieson M. Bourque,

Parathyroid Disorders and Treatments

Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies define the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis.